ALENIGLIPRON [USAN]

Structure Therapeutics is developing aleniglipron, an oral small-molecule GLP-1 receptor agonist. The company reported positive Phase 2 ACCESS II topline (NCT06703021, n=85) in March 2026 showing placebo-adjusted mean weight loss of 16.3% at the 180 mg dose at 44 weeks [2][11], the highest efficacy reported for any oral GLP-1 to date and competitive with injectable class leaders. Structure has received end-of-Phase 2 FDA feedback and guides Phase 3 initiation in Q3 2026 [11]. The primary Phase 2b ACCESS trial (NCT06693843, n=220, 36-week endpoint) remains active [1]. Commercial context has shifted sharply: Lilly's orforglipron was FDA-approved as Foundayo on April 1, 2026 [9] following ATTAIN-1 Phase 3 data of 12.4% weight loss at 72 weeks [7], meaning aleniglipron enters Phase 3 against an already-approved oral GLP-1 rather than racing to file first. Injectable GLP-1s cleared north of $50B in 2024 sales, and pill dosing meaningfully expands the addressable population. Structure (ticker GPCR) reported $1.5B in cash and short-term investments as of March 31, 2026 with runway guided through end of 2028 [10], enough to self-fund the initial obesity Phase 3 without a distressed partnership. If the ~16% figure holds at Phase 3 duration, Structure has a credible best-in-class oral GLP-1; if it compresses to Foundayo levels or lower, the differentiation story weakens materially.

Aleniglipron (formerly GSBR-1290) is a novel oral small-molecule GLP-1 receptor agonist, not an approved drug pursued in a new indication. Structure Therapeutics runs the program through wholly owned subsidiary Gasherbrum Bio. In March 2026 the company reported positive topline data from Phase 2 ACCESS II (NCT06703021, n=85), showing placebo-adjusted weight loss of 14.7% (120 mg), 16.3% (180 mg), and 16.0% (240 mg) at 44 weeks (all p<0.0001), with placebo participants gaining 1.1% [2][11]. Both curves showed no evidence of plateau. Tolerability was described as consistent with the injectable GLP-1 class and no off-target safety events were flagged. The ACCESS program was subsequently published in Nature Medicine in June 2026 [6]. Structure received end-of-Phase 2 FDA feedback and plans to initiate a Phase 3 chronic weight management program in Q3 2026 [11]. The Phase 2b ACCESS trial (NCT06693843, n=220, 36-week primary endpoint of percent change in body weight) remains active, not recruiting [1]. Two additional Phase 2s are ongoing: a type 2 diabetes study (NCT07400588, n=58) [3] and a body composition study using DXA (dual-energy X-ray absorptiometry, the same scan used to measure bone density) endpoints (NCT07169942, n=71) [4]. No FDA breakthrough or fast-track designations have been publicly disclosed.

GLP-1 (glucagon-like peptide 1) is a hormone the gut releases after a meal that tells the pancreas to make insulin and tells the brain that eating is enough. Drugs that mimic GLP-1 lower blood sugar in type 2 diabetes and cause substantial weight loss by suppressing appetite and slowing gastric emptying. The target, the GLP-1 receptor, is one of the most validated in medicine. Injectable GLP-1 agonists (semaglutide sold as Ozempic and Wegovy; tirzepatide sold as Mounjaro and Zepbound, which hits GLP-1 and a second gut hormone receptor called GIP) drove more than $50B in 2024 sales combined and delivered 15-22% average weight loss in Phase 3 trials. The unsolved problem historically was oral delivery. Peptide GLP-1s like semaglutide degrade in the stomach, which is why they need injection or, in Novo's oral Rybelsus, absorption enhancers that force fasted morning dosing and limit dose escalation. Aleniglipron is a small molecule that binds the same receptor as GLP-1 itself without being a peptide, so it survives oral dosing without special formulation tricks. Lilly's orforglipron (Foundayo) is the first oral small-molecule GLP-1 to reach FDA approval, cleared April 1, 2026 [9]. The scientific question for aleniglipron is not whether the target works. It is whether this specific molecule delivers competitive weight loss with tolerable GI side effects at scale. Nausea and vomiting are the dose-limiting toxicity for the entire class, and small molecules can engage gut receptors differently than injected peptides, sometimes with a worse GI profile at matched exposure.

The Phase 2b ACCESS trial (NCT06693843) is a dose-ranging study, meaning it tests multiple doses against placebo to identify the best dose to carry into a larger Phase 3 trial. Enrollment is 220 adults with BMI at or above 30, or BMI at or above 27 with a weight-related comorbidity, with a primary endpoint of percent change in body weight from baseline to Week 36 [1]. Sponsor is Gasherbrum Bio, a wholly owned Structure Therapeutics subsidiary. Enrollment is complete and the trial is running through the 36-week timepoint. The related Phase 2 ACCESS II study (NCT06703021, n=85) tested 120, 180, and 240 mg once-daily doses against placebo out to 44 weeks and reported positive topline in March 2026 [2][11]. Design across the ACCESS program mirrors what Lilly ran for orforglipron before advancing to Phase 3. Comparator is placebo, which is appropriate for dose-finding but means Structure will need cross-trial comparisons against semaglutide, tirzepatide, and Foundayo [9] to argue competitive positioning at Phase 3 investor communications. The parallel body composition study (NCT07169942) uses DXA imaging (dual-energy X-ray absorptiometry, capable of separating fat mass from lean muscle mass) to look at where weight loss comes from [4]: a persistent criticism of GLP-1 weight loss is muscle loss, and clean DXA data showing fat-preferential loss would strengthen the eventual label discussion. The T2D Phase 2 (NCT07400588) at n=58 is small and early, primarily a safety and pharmacokinetics study [3]. The overall program is well-scoped for a mid-cap biotech with obesity as the anchor indication.

Our model estimates a 10% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk has partially resolved but is not gone. ACCESS II Phase 2 delivered 16.3% placebo-adjusted weight loss at 44 weeks [11], the highest reported for any oral GLP-1 and above Foundayo's 12.4% at 72 weeks in ATTAIN-1 Phase 3 [7]. The residual efficacy risk is whether the effect holds at Phase 3 scale and 68-72 week duration. Historically, small-molecule GLP-1 effects can compress in larger, longer trials. If Phase 3 delivers below 10-12%, the differentiation story against Foundayo collapses. Safety risk centers on GI tolerability and liver function. Pfizer discontinued danuglipron in April 2025 after an asymptomatic but potentially drug-induced liver injury in a single participant [8]; any comparable signal in aleniglipron Phase 3 would hit valuation immediately. GLP-1s cause nausea and vomiting at rates that push double-digit discontinuation in Phase 3, and small molecules can amplify gut effects. Class-level concerns about lean mass loss and, at the margin, thyroid C-cell hyperplasia carried over from the peptide labels, add background noise. Execution risk is materially lower than typical for a mid-cap at this stage: Structure reported $1.5B in cash and short-term investments as of March 31, 2026 with runway guided through end of 2028 [10], enough to self-fund a global obesity Phase 3 without a distressed partnership. Commercial risk is the sharpest bear case: Foundayo is FDA-approved as of April 1, 2026 [9] and will build market access ahead of any aleniglipron filing. Retatrutide, Lilly's triple GLP-1/GIP/glucagon agonist in Phase 3, showed ~24% weight loss in Phase 2 [12], setting an injectable-class ceiling that will pressure any oral candidate with sub-15% Phase 3 data. Payers are tightening obesity coverage and semaglutide patent loss in the early 2030s will bring generic pricing pressure.

Worth watching closely. The story has shifted materially in the last few months. ACCESS II Phase 2 already delivered the best oral GLP-1 efficacy print to date (16.3% at 44 weeks) [11], and Structure has the cash ($1.5B, runway through 2028) [10] to run Phase 3 independently rather than being forced into a distressed partnership. Specific data to watch next: Phase 3 protocol design (dose selected, endpoint duration; a 68-72 week readout to match ATTAIN-1 would enable a direct head-to-head narrative), the ACCESS Phase 2b readout (NCT06693843, n=220, 36-week endpoint) [1], the DXA body composition readout [4], and any liver enzyme signal once Phase 3 scale is reached. A Phase 3 result at 14% or higher at 68-72 weeks with a GI profile similar to injectable semaglutide would put aleniglipron in genuine best-in-class oral positioning against Foundayo's 12.4% [7][9]. A result at 10% or below, or any liver signal echoing danuglipron [8], would collapse the differentiation story now that an approved oral alternative exists. Retatrutide (~24% weight loss in Phase 2) [12] is the longer-term ceiling; it is injectable, but a benchmark that acquirers and payers will use. Check back after Structure's next earnings call for Phase 3 design specifics and confirmed initiation timing (currently guided for Q3 2026 [11]), and again on any Phase 3 primary readout. At this cash position, Structure is more likely a strategic partnership or acquisition target than a company forced to shelve the asset. Base case: aleniglipron reaches Phase 3, holds enough of the ACCESS II efficacy to differentiate at read, and either launches independently or is licensed at a premium into a large pharma without an oral GLP-1 (which is most of them, outside Lilly). Data point not yet public that would change the read: specific dose selected for Phase 3 and the exact primary endpoint duration.